On the surface, America looks like an unrivaled success story. Yet beneath the headline numbers lies an economy increasingly dependent on foreign production, hollowed out in critical industries, and unable to provide secure, high-wage work for many of its citizens.
America is finally getting serious about its dangerous dependence on foreign-made generic drugs.
The Trump administration’s section 232 investigation into medical devices and personal protective equipment is a vital step toward ensuring America takes back control over its production and domestic supply of critical medical products.
The hearing continued the committee’s efforts to examine and reduce America’s severely dangerous over-dependence on foreign-manufactured generic drugs and address vulnerabilities in the nation’s pharmaceutical supply chain.
Move seen as a critical step to protect U.S. manufacturing, American jobs, and national security WASHINGTON, D.C. — The Coalition for a Prosperous America (CPA)
This year, GM swapped positions with Ford. GM is the most exposed to China while Ford has declined to No. 5.
CPA’s chief economist emeritus, Jeff Ferry, has gone back to school in his semi-retirement years. This time, though, it was a speaking gig at the University of Florida’s new Semiconductor Institute in Gainesville.
The era of global dependency on the CCP is over. For decades, Wall Street, multinational corporations, and globalist institutions helped finance China’s rise at the direct expense of American workers, manufacturers, and national security.
CPA Economist Andrew Rechenberg gave his testimony and answered questions in a four- panelist hearing. It was arguably the most agreeable hearing in years. A bipartisan consensus on America’s generic drug supply chain is nearly fully formed now.
Titled “The New Biotech Cold War: The U.S. Medicine Can’t Afford to Fall Behind China,” the report shows how U.S. biotech – long a pillar of national strength – no longer has a guaranteed edge globally.
